2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-4-fluoro-6-(1-oxo-3,4,5,6,7,8-hexahydrobenzothieno[2,3-c]pyridin-2(1H)-yl)benzyl Acetate → 5-[5-Fluoro-2-(hydroxymethyl)-3-{(8-(5-(4-methylpiperazin-1-yl)pyridine-2-ylamino)imidazo[1,2-a]pyridin-6-yl)}phenyl]-8-thia-5-azatricyclo[7.4.0.02,7]trideca-1(9),2(7)-dien-6-one

Participants

Reaction Steps

Following the procedures as described for compound 101, 103g (499 mg, 1.0 mmol), and 6-chloro-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)imidazo[1,2-a]pyridin-8-amine 101b (342 mg, 1.0 mmol) were reacted to give 103 as a white solid (220 mg, 35%). LCMS: [M+H]+ 638. 1H NMR (500 MHz, CDCl3) δ 8.22 (s, 2H), 7.96 (d, J=2.5, 1H), 7.83 (s, 1H), 7.63 (d, J=1.0, 1H), 7.57 (d, J=1.0, 1H), 7.30 (dd, J=3.0, 9.0, 1H), 7.24 (dd, J=2.5, 9.0, 1H), 7.03 (dd, J=3.0, 9.0, 1H), 6.92 (d, J=8.5, 1H), 4.57 (d, J=11.5, 1H), 4.35 (t, J=8.5, 1H), 4.21 (s, 1H), 4.09-4.15 (m, 1H), 3.87-3.92 (m, 1H), 3.16 (t, J=5.0, 4H), 2.85-3.02 (m, 4H), 2.60 (t, J=5.0, 4H), 2.51-2.57 (m, 2H), 2.37 (s, 3H), 1.85-1.95 (m, 4H)

Provenance & Evidence